Short-term statin use prevents contrast-induced acute kidney injury

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.
Takeaway

  • Short term statin treatment in effective in preventing contrast-induced acute kidney injury (CI-AKI) in patients undergoing coronary angiography or percutaneous coronary intervention.

Study design

  • Meta-analysis that included 21 randomized controlled trials involving 7746 patients.
  • The goal was to assess the role of short-term statin treatment in the prevention of CI-AKI and clinical adverse events in patients undergoing coron ary angiography or percutaneous coronary intervention .

Key results
  • Short-term statin treatment significantly reduced the risk of CI-AKI [risk ratio (RR) 0.57; 95 % confident interval (CI) 0.47-0.69; p < 0.00001) and was associated with a lower post-procedural serum creatinine level and a higher estimated glomerular filtra-tion rate.
  • High-dose statins resulted in a lower incidence of CI-AKI than the lower-dose statins.
  • The benefit was seen across subgroups for patients at risk of CI-AKI, statin-naïve patients, and East Asians, regardless of statin type, definition of CI-AKI, use of N-acetylcysteine (NAC) and hydration, and osmolality of contrast.
  • Statin use did not seem to affect the incidence of adverse events.
Limitations
  • Due to the limited study numbers and pop-ulation sizes, the power of the analyses may be restricted.
  • There was significant heterogeneity among studies for some outcomes.
  • Only 1 study reported data on adverse events caused by statins.

Why This Matters

  • Short term statin use appears to prevent the development of CI-AKI in this population and can be considered for patients undergoing these procedures, especially for those at increased risk of this complication.